Stephen Stonehouse
Family Medicine · Philadelphia, PANPI 1285904706
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 168 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 18.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,105 and has fallen 98.3% since, to $19 in 2025.
Across 168 payments — averaging $16.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$519
- Novo Nordisk$383
- AbbVie$311
- Bausch Health US, LLC$282
- Amarin Pharma, Inc.$210
- Merck$201
- plus $931 from 18 others
What the payments were for
- Food & beverage$2,837100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 30 | $519 |
| Novo Nordisk | 26 | $383 |
| AbbVie | 20 | $311 |
| Bausch Health US, LLC | 14 | $282 |
| Amarin Pharma, Inc. | 14 | $210 |
| Merck | 10 | $201 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $126 |
| Amgen | 6 | $107 |
| GSK | 5 | $95 |
| Boehringer Ingelheim | 4 | $76 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $75 |
| Exact Sciences | 4 | $72 |
| AstraZeneca | 5 | $68 |
| Kowa Pharmaceuticals America, Inc. | 5 | $61 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $56 |
| Biohaven Pharmaceuticals, Inc. | 2 | $48 |
| Astellas Pharma US Inc | 1 | $27 |
| Impel Pharmaceuticals Inc. | 1 | $21 |
| Dermira, Inc. | 1 | $18 |
| Novartis | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Endo Pharmaceuticals Inc. | 1 | $18 |
| Vistapharm, Inc. | 1 | $13 |
| Phadia US Inc. | 1 | $13 |
How this compares
$2,837 in reported general payments places this provider in the 80th percentile of 4,967 family medicine providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 105 | $114,012 |
| TrulicityDulaglutide | 74 | $89,208 |
| EliquisApixaban | 71 | $72,167 |
| JardianceEmpagliflozin | 54 | $67,984 |
| JanuviaSitagliptin Phosphate | 37 | $43,593 |
| FarxigaDapagliflozin Propanediol | 47 | $43,385 |
| MounjaroTirzepatide | 25 | $29,951 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 42 | $27,887 |
| XareltoRivaroxaban | 18 | $21,108 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 122 | $17,555 |
| RybelsusSemaglutide | 11 | $16,090 |
| LinzessLinaclotide | 20 | $15,908 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 11 | $14,904 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 55 | $7,865 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 243 | $6,815 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $383 | $130,102116 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $519 | $119,15999 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $76 | $82,88765 claims |
| MerckJanuvia | $201 | $43,59337 claims |
| AstraZenecaFarxiga | $68 | $43,38547 claims |
| GSKTrelegy Ellipta | $95 | $27,88742 claims |
| AbbVieLinzess | $311 | $15,90820 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Philadelphia
- Deborah WittPhiladelphia$226K
- Michael AttanasioPhiladelphia$214K
- Jonah MinkPhiladelphia$145K
- Celia EzidiegwuPhiladelphia$118K
- Glenn RosenPhiladelphia$61K
- Jessica DefflerPhiladelphia$56K
- Casey LaffertyPhiladelphia$55K
- Margot SavoyPhiladelphia$31K
- Neil SkolnikJenkintown$904K
- Lisa EspinozaNew Hope$722K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.